Myriad Genetics, Inc. · NASDAQ:MYGN

Myriad Genetics — Q3 2026 Earnings Presentation

28 slides from Myriad Genetics's earnings presentation, Nov 4, 2026

  1. Slide 1: Third Quarter 2026 Earnings Call

    Third Quarter 2026 Earnings Call November 4, 2026 ©2026 Myriad Genetics, Inc.

  2. Slide 2: Forward-looking statements and Non-GAAP financial measures

    Forward-looking statements and Non-GAAP financial measures Some of the FORWARD-LOOKING STATEMENTS AND DISCLAIMERS information presented These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these here today contains

  3. Slide 3: Progress

    Progress Sam Raha PRESIDENT AND CHIEF EXECUTIVE OFFICER ©2026 Myriad Genetics, Inc. 3

  4. Slide 4: Third quarter 2026 performance and takeaways

    Third quarter 2026 performance and takeaways Q3'26 revenue benefits from CCC Q3'26 profitability improves Sale of Prenatal business to mix & avg revenue per test from Q2'26 unlock significant value Q3‘26 revenue of $202.7M reflects 67.9% gross margins in Q3‘26; Announced sale of Prenatal YOY volume

  5. Slide 5: Prenatal Health: Unlocking potential value through announced divestiture

    Prenatal Health: Unlocking potential value through announced divestiture Deal rationale and expected benefits Improves Myriad’s liquidity, accretive to revenue 1 growth/profitability Maximizes benefits for patients, clinicians, 2 employees and shareholders Enables increased focus on the 3 Cancer Car

  6. Slide 6: Third Quarter 2026 Business Update

    Third Quarter 2026 Business Update ©2026 Myriad Genetics, Inc. 6

  7. Slide 7: Cancer Care Continuum: Continuing Hereditary Cancer Test volume growth; Progressing MRD

    CANCER CARE CONTINUUM Continuing Hereditary Cancer Test volume growth; Progressing MRD Operational results: Third quarter 2026 and recent highlights $124M Q3‘26 revenue • Another record high volume quarter for • unaffected HCT in last three years Continued expansion of hereditary cancer ~98K Q3‘26 t

  8. Slide 8: Mental Health: Maintaining leadership with disciplined investment and focus

    M E N TA L H E A LT H Maintaining leadership with disciplined level of investment and focus Operational results: Third quarter 2026 $40M Q3‘26 revenue and recent highlights • Q3’26 GeneSight revenue increased 2% YOY, reflecting a (1)% YOY change in average revenue ~141K per test Q3‘26 test volume •

  9. Slide 9: Prenatal Health: Announced divestiture positive for stakeholders

    P R E N ATA L H E A LT H Announced Prenatal Health divestiture: positive for stakeholders Third quarter 2026 Operational results: and recent highlights • October 20 announced definitive agreement to sell Prenatal Health test business to Labcorp; target close by early 2027 $39M Q3‘26 revenue ~138K Q3

  10. Slide 10: On-track with key 2026 product publications, submissions and launches

    On-track with key 2026 product publications, submissions and launches HCT Prostate Cancer Precise MRD Prenatal Health • Launched MyRisk • Launched Prolaris + AI Initiated commercial testing for Reported out on Disease Specific test; Q2’26 select customers; March‘26 FirstGene CONNECTOR Panels; H1‘26

  11. Slide 11: Financial Update

    Financial Update Ben Wheeler CHIEF FINANCIAL OFFICER ©2026 Myriad Genetics, Inc. 11

  12. Slide 12: Third quarter 2026 performance

    Third quarter 2026 performance Demonstrating progress with multiple initiatives, including revenue cycle management Q3'26 revenue benefits from mix, average test revenue Average revenue per test improved in Q3’26 YOY A Look at Myriad Post Sale Positive demand in CCC continues • Positioned for higher

  13. Slide 13: Average revenue per test

    Recent initiatives contribute to improving Q3’26 average revenue per test Hereditary Cancer Test (HCT) 9% Change in average revenue per test in Q3’26 over Q2’26 Comprehensive action plan Average revenue per test $1,250 0% RCM improvements -5% Optimizing workflows to accelerate cash collections $1,10

  14. Slide 14: Continued strong gross profit and healthy liquidity position

    Continued strong gross profit and healthy liquidity position Additional highlights: Sale of Prenatal Health Gross Profit Adj EBITDA1 Liquidity position2 business expected to add Generated approximately Generated a loss of Access to ~$200M cash $138M $5M ~$182M As of September 30, 2026 Generated adj

  15. Slide 15: Prenatal Health divestiture expected to be a catalyst for unlocking value

    Prenatal Health divestiture expected to be a catalyst for unlocking value P&L impact and Potential Benefits (first 12-months post close): guidance considerations Prenatal Health generated revenue of $165M*; gross margins of revenue growth: 100+ ~40%* basis points (YOY) Transaction details Potential

  16. Slide 16: Raising mid-point of full year 2026 revenue guidance range

    Raising mid-point of full year 2026 revenue guidance range All figures in millions, except percentages UPDATED 2026 REVENUE GUIDANCE $780 - $790M Previous $770 - $790M Guidance reflects positive CCC and CCC + Mental Health Prenatal Health Mental Health current business trends $620M – $630M ~$160M pa

  17. Slide 17: Closing Comments

    Closing Comments Sam Raha PRESIDENT & CHIEF EXECUTIVE OFFICER ©2026 Myriad Genetics, Inc. 17

  18. Slide 18: Taking important actions to drive accelerated profitable growth

    Taking important actions to better position Myriad to drive accelerated profitable growth STRATEGIC ACTIONS STRENGTHEN Divest Prenatal Health business Financial profile Mitigate payer friction Predictability Focus on the cancer Increase org efficiency, care continuum productivity, and scalability ©2

  19. Slide 19: Q&A

    Q&A ©2026 Myriad Genetics, Inc. 19

  20. Slide 20: Appendix

    Appendix ©2026 Myriad Genetics, Inc. 20

  21. Slide 21: Reconciliation of GAAP to Non-GAAP: Adjusted Gross Margin

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Gross Margin (unaudited data in millions) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Adjusted Gross Margin Gross Profit $ 137.7 $

  22. Slide 22: Reconciliation of GAAP to Non-GAAP: Adjusted Operating Expenses

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Operating Expenses (unaudited data in millions) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Adjusted Operating Expenses Operating

  23. Slide 23: Reconciliation of GAAP to Non-GAAP: Adjusted Operating Expenses (Cont.)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Operating Expenses (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Expense related to goodwill and long-live

  24. Slide 24: Reconciliation of GAAP to Non-GAAP: Adjusted Net Income (Loss)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Net Income (Loss) (unaudited data in millions, except per share amounts) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Adjusted Net

  25. Slide 25: Reconciliation of GAAP to Non-GAAP: Adjusted Net Income (Loss) (Cont.)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025– Adjusted Net Income (Loss) (Cont.) (1) To determine Adjusted Income (Loss) Per Share. (2) Represents recurring amortization charges resulting from the acquisition of intangible asse

  26. Slide 26: Reconciliation of GAAP to Non-GAAP: Adjusted EBITDA

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted EBITDA (unaudited data in millions) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Adjusted EBITDA Net Loss $ (43.9) $ (27.4) $ (121.

  27. Slide 27: Reconciliation of GAAP to Non-GAAP: Adjusted EBITDA (Cont.)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted EBITDA (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Consists of depreciation expense recognized during th

  28. Slide 28: Reconciliation of GAAP to Non-GAAP: Adjusted Free Cash Flow

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Free Cash Flow (unaudited data in millions) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Adjusted Operating and Free Cash Flow Net

Myriad Genetics — Q3 2026 Earnings Presentation on 6ix